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Materials and Methods 
 
Reagents and antibodies 
Cycloheximide, dithiobis(succinimidylpropionate) (DSP; Lomant’s reagent), MG132 and 
complete protease inhibitor cocktail tablet were from Sigma, Thermo Scientific, Calbiochem and 
Roche, respectively. Antibodies to the following antigens were used for immunoblotting and/or 
immunoprecipitation: anti-flag M2 (Sigma, F1804 or Stratagen, 200471), anti-c-Myc-9E10 
(Sigma, M5546), anti-hemaggutinin (ha) tag (Sigma, H9658 or H6958), anti-tubulin (Sigma, 
T5168), anti-Teb4 (Bethyl Laboratories, A304-171A), anti-ubiquitin (Stressgen, SPA-203), 
anti-Naa20 (Nat5) (Santa Cruz Biotechnology, sc-100645), anti-Naa60 (Nat15) (Abcam, 
ab103800), anti-phospho-p44/42 Erk1/2 (Cell Signaling Technologies, Ab9101), anti-p44/42 
Erk1/2 (Cell Signaling Technologies, Ab9102) and anti-Rgs2 (Abgent, AT3628a). Secondary 
antibodies for immunoblotting were HRP-conjugated goat anti-rabbit (Bio-Rad, 170-6515) or 
anti-mouse (Bio-Rad, 170-6516), and either ECL Prime Western Blotting Detection System (GE 
Healthcare) or Clarity Western ECL substrate (Bio-Rad) were used, according to manufacturers’ 
protocols. The following reagents were used for immunoprecipitation and GST-pulldown assays: 
anti-flag M2 affinity gel (Sigma, A2220), Dynabeads Protein A and G (Life Technologies), and 
Glutathione Hicap (Qiagen). For determining the state of Nα-terminal acetylation 
(Nt-acetylation) of Rgs2, human Rgs2 (purified from the HEK293 cell line) was purchased from 
Origene (TP302781) and analyzed using mass spectrometric (MS) techniques (see below). 
 
Yeast strains, media, and genetic techniques 
The S. cerevisiae strains used in this study are described in Table S1. Standard techniques 
(27, 28) were employed for strain construction and transformation. S. cerevisiae media included 
YPD medium (1% yeast extract, 2% peptone, 2% glucose; only most relevant components are 
cited); SD medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% glucose); and 
synthetic complete (SC) medium (0.17% yeast nitrogen base, 0.5% ammonium sulfate, 2% 
glucose), plus a drop-out mixture of compounds required by a given auxotrophic strain. The 
S. cerevisiae strain CHY367 (naa20::natNT2) was constructed using PCR-mediated gene 
targeting (29) and the natNT2 module (30) in the strain JD53 (see Table S1). 
 
Cell culture, transfection and RNA interference 
Human HeLa cell line was grown in Dulbecco's Modified Eagle Medium (DMEM) 
(Ronza) supplemented with 10% fetal bovine serum (FBS) (HyClone) and penicillin 
(100 U/ml)/streptomycin (100 g/ml) (HyClone) in a 5% CO2 incubator at 37C. Transfections 
with DNA plasmids or siRNA oligoribonucleotides were carried out using Lipofectamine-2000 
(Life Technologies) according to the manufacturer’s instructions. For RNA interference (RNAi), 
HeLa cells were seeded on day 1 at 2 × 105 cells per well in 6-well cell culture plates (SPL Life 
Sciences, Korea) containing DMEM and 10% FCS. After incubations for 24 hr, cells were 
transfected with 100 nM of either human Teb4 siRNA, or Naa20 siRNA, or Naa60 siRNA, or 
non-targeting (control) siRNA (Santa Cruz Biotechnology, sc-91789, sc-37007, sc-62662, and 
sc-93037, respectively), using Lipofectamin-2000 according to the manufacturer’s instructions. 
 
DNA constructs and primers 
E. coli DH5α strain was used for cloning and maintaining plasmids (Table S1). Solg 
Pfu-X DNA polymerase (SolGent, Korea) was employed for PCR. The plasmids and PCR 
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primers used in this study are described in Tables S2 and S3, respectively. To express human 
MX-Rgs2 (X=Gln, Leu, Arg) in mammalian cells, we used the pCH766, pCH767 and pCH768 
plasmids, which expressed, respectively, MQ-Rgs2ha, ML-Rgs2ha and MR-Rgs2ha from the PCMV 
promoter and were a gift from Dr. R. Neubig (Univ. of Michigan Medical School, East Lansing, 
MI) (11). To construct pCH821, which expressed PQ-Rgs2ha (MPQ-Rgs2ha), the 
MPQ-RGS2ha-encoding DNA fragment was produced by PCR from the plasmid pCH766 
(Table S2) using the primer pair OCH1091/OCH1100. This fragment was digested with 
KpnI/XhoI and ligated into KpnI/XhoI-cut pCH766.  
To construct the low copy (CEN-based) pCH5050 and pCH5051 plasmids, which 
expressed MQ-Rgs2ha and ML-Rgs2ha in S. cerevisiae from the PCUP1 promoter, the relevant 
Rgs2 DNA fragments were amplified from pCH766 using the primer pairs OCH5070/OCH5073 
and OCH5071/OCH5073, respectively. The resulting PCR products were digested with 
BamHI/SacI and ligated into BamHI/SacI-cut pCH692, a pRS316-based low copy plasmid 
containing the PCUP1 promoter.  
To construct pCH879 and pCH881, which expressed, from the PCMV promoter in 
mammalian cells, the wild-type human Teb4 and its catalytically-inactive mutant Teb4C9A (both 
of them were C-terminally tagged with triple flag plus His6), a DNA sequence encoding the 
above “double” epitope was produced by annealing the complementary primers 
OCH1265/OCH1266 (Table S3). The resulting DNA, encoding triple flag plus His6, was 
digested with HindIII/AflII and ligated into HindIII/AflII-cut pCH759 and pCH760, which 
encoded, respectively Teb4 and Teb4C9A in the pcDNA3.1-myc-His(-) A vector (24). The 
plasmid pCH3056, which encoded full-length MQ-Rgs2 whose C-terminus was fused to GST, 
was constructed by producing, at first, a DNA fragment from pCH766 (Table S2), using PCR 
and the primer pair OCH3006/OCH3013. This fragment was digested with NdeI/BamHI. 
Furthermore, a DNA fragment was produced by PCR from pGEX4T-3 and the primer pair 
OCH3015/OCH1514, followed by digestion of the resulting fragment with BamHI/XhoI. The 
above two fragments were ligated into NdeI/XhoI-cut pET30a, yielding the plasmid pCH3056. 
To construct the plasmid pCH3080, which expressed, from the IPTG-inducible T7lac 
promoter in E. coli, a fusion between the N-terminal 10 residues of MQ-Rgs2 and the GST 
moiety, a DNA fragment was produced by PCR using pCH3056 (Table S2) and the primer pair 
OCH3095/OCH1514 (Table S3). The resulting fragment was digested with NdeI/XhoI and 
ligated into NdeI/XhoI-cut pET30a (Table S2).  
To construct pCH3132 that expressed the human muscarinic acetylcholine receptor M3 
from the PCMV promoter, DNA sequence encoding M3 was PCR-amplified from a human 
HEK293T cDNA library using primer pairs OCH3178/OCH3179. The resulting PCR fragment 
was digested with BamHI/XbaI and ligated into BamHI/XbaI-cut pCH61. To clone pCH5064 that 
expressed the human guanidine-nucleotide binding protein G(q) subunit alpha (Gαq) from the 
PCMV promoter, DNA sequence encoding Gαq was also PCR-amplified from HEK293T cDNA 
library using primer pairs OCH5090/OCH5091. The resulting DNA fragment was digested with 
KpnI/XhoI and ligated into KpnI/XhoI-cut pCH61, yielding pCH5064. Construction details for 
other plasmids are available upon request. All final constructs were verified by DNA sequencing. 
 
Cycloheximide-chase assays and immunoblotting 
For immunoblotting, HeLa cells were lysed by incubating them on ice for 20 min in the 
TLB lysis buffer (1% Triton X100, 50 mM NaCl, 2 mM Na-EDTA, 50 mM Tris-HCl, pH 7.4), 
containing complete protease inhibitor mixture (Roche). After precipitating cell debris by 
centrifugation at 11,200g for 10 min at 4°C, total protein concentrations in the supernatants were 
determined using Bradford or DC protein assay (Bio-Rad). Identical total amounts of protein in 
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each sample were heated at 95°C for 10 min or at 37C for 15 min (the samples for 
immunoblotting of Teb4 were incubated, instead, at 37C for 20 min) in 1x SDS-sample buffer, 
followed by Tris-glycine-SDS-10% PAGE or Tris-glycine-4-20% PAGE. For immunoblotting 
analyses of Teb4, protein samples were fractionated by Tris-glycine-SDS-6% PAGE or by 
Tris-glycine-SDS-8% PAGE. Fractionated proteins were electroblotted to Immobilon-P 
membranes (Millipore) using mini-transblot cell (Bio-Rad), and were analyzed by 
immunoblotting with indicated antibodies, followed by secondary antibodies described in the 
first section above. Immunoblots were detected using Clarity Western ECL substrate (Bio-Rad) 
or ECL Plus Western blotting Detection System (GE Healthcare). 
Cychloheximide (CHX)-chase assays with HeLa cells were set up on day 1 at 2 × 105 
cells/well in 6- or 12-well cell culture plates (SPL Life Sciences, Korea) containing DMEM and 
10% FCS. After 24-hr incubation at 37°C, the cells were treated with CHX at the final 
concentration of 0.1 mg/ml, harvested by centrifugation at each time point, and lysed in RIPA 
buffer (0.1% NP40, 0.15 M NaCl, 5 mM Na-EDTA, 1 mM dithiothreitol (DTT), 50 mM HEPES, 
pH 7.5, plus the “complete protease inhibitor cocktail” (Roche)). Equal amounts of total protein 
were fractionated by Tris-glycine SDS-4-20 % PAGE, followed by immunoblotting with 
indicated antibodies. In particular, immunoblotting with antibody to -tubulin was used as a 
loading control for all immunoblotting experiments.  
CHX-chases with S. cerevisiae cells were performed as previously described (13, 15), 
with slight modifications. S. cerevisiae were grown to A600 of 0.8-1.0 at 30C in selective media 
appropriate for a plasmid(s) carried by a strain. Cells were harvested by centrifugation at 11,200g 
for 1 min and thereafter resuspended in fresh YPD to a final concentration of A600 of 1.0, 
followed by the treatment with CHX at the final concentration of 0.2 mg/ml. At indicated times, 
cell samples (corresponding to 1 ml of cell suspension at A600 of 1) were harvested by 
centrifugation for 1 min at 11,200g, and were resuspended in 0.8 ml of 0.2 M NaOH and 
incubated for 20 min on ice, followed by centrifugation for 1 min at 11,200g. Pelleted cells were 
resuspended in 80 l of HU buffer (8 M urea, 5% SDS, 1 mM Na-EDTA, 0.1 M DTT, 0.005% 
bromophenol blue, 0.2 M Tris-HCl, pH 6.8) containing 1x protease inhibitor cocktail “for use 
with fungal and yeast extracts” (Sigma), and heated for 10 min at 70C. After centrifugation for 
5 min at 11,200g, 10 l of supernatant was subjected to SDS-10% PAGE, followed by 
immunoblotting with anti-ha (1:2,000) and anti-tubulin (1:2,000) antibodies. Quantification of 
immunoblotting data was carried out using GelQuantNET 
(http://biochemlabsolutions.com/GelQuantNET.html). 
 
Cycloheximide-chase assays with co-expressed Rgs2ha and Gαqha2 
To determine whether Gαqha2, a C-terminally doubly ha-tagged Gαq, could stabilize 
MQ-Rgs2ha against degradation in HeLa cells, cultures at ~90% confluence in 6-well (35-mm) 
plates were transiently cotransfected with 0.5 μg of pCH766 (expressing MQ-Rgs2ha) and 2.5 μg 
of either pCH5064 (expressing Gαqha2) or pCH61 (vector alone) per well, in the serum-free Opti-
MEM medium (Gibco). After 5-hr transfection, the medium was replaced by DMEM containing 
10% FBS. After incubation for 24 hr at 37C, the cells were treated with CHX at the final concen
tration of 0.1 mg/ml, harvested by centrifugation at each time point of a chase, and  
lysed in RIPA buffer (0.1% NP40, 0.15 M NaCl, 5 mM Na-EDTA, 1 mM dithiothreitol (DTT),  
50 mM HEPES, pH 7.5, plus the “complete protease inhibitor cocktail” (Roche)). Equal  
amounts of total protein were fractionated by Tris-glycine SDS-12 % PAGE, followed by  
immunoblotting with anti-ha or anti-tubulin antibodies. Immunoblotting with antibody to  
-tubulin was used as a loading control for all immunoblotting experiments.  
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35S-pulse-chase assays 
HeLa cell cultures (at ~75% confluence) were transfected with 2.5 μg of a plasmid per 
35-mm well, using Lipofectamine-2000 according to the manufacturer’s protocol. 48 hr after 
transfection cells were pulse-labeled for 15 min with [35S]-L-methionine (0.1 mCi/ml, MP 
Biomedicals) in DMEM lacking methionine. CHX and 5 mM unlabeled methionine were then 
added to the final concentration of 0.1 mg/ml and 5 mM, respectively. Cells in an entire 35-mm 
well were lysed at the indicated time points of a chase by rapid scraping into 0.1 ml of TSD 
buffer (1% SDS, 5mM DTT, 50 mM Tris-HCl, pH7.4) and snap-freezing in liquid nitrogen. 
Samples were then heated at 95°C for 10 min and diluted with 10 volumes of TNN buffer 
(0.5% NP40, 0.25M Na Cl, 5 mM Na-EDTA, 50 mM Tris-HCl, pH 7.4) containing the 
“complete protease-inhibitor mixture” (Roche). The amounts of 35S in the 10% CCl3COOH-
insoluble fraction of each sample were then measured by liquid scintillation counting. For 
immunoprecipitation, the samples were adjusted to contain equal amounts of total 35S and then 
added to 20 μl of anti-ha agarose (Sigma). Suspensions of beads were incubated by rocking at 
4°C for 2 hr, washed 3 times in TNN buffer, and once in 10 mM Tris-HCl, pH 8.5. Final samples 
were eluted by 30 μl of SDS-PAGE sample buffer, including the heating at 95°C for 5 min, 
followed by clarification through centrifugation at 11,200g for 1 min. 10 l of each of the 
resulting samples were separated by SDS-4-20% PAGE (Bio-Rad, followed by autoradiography 
using Typhoon 9400 PhosphorImager (GE Healthcare) and quantification of autoradiograms 
with ImageQuant (GE Healthcare). 
 
RNA isolation and quantitative RT-qPCR 
Total RNA was isolated from HeLa cells using an RNeasy Mini kit (Qiagen), according 
to the manufacturer’s instructions. 2 μg of total RNA was reverse-transcribed into cDNA with 
oligo-dT as a primer by using Promega cDNA reverse transcription kit. Quantitative real-time 
PCR was performed in 20-μl reactions containing 10 ng of the cDNA sample, 50 nM forward 
and reverse primers, and the SYBR Green Master Mix (Applied Biosystems). Primers for human 
Rgs2 and β-actin genes were designed using GenScript Real-time PCR Primer Design tool. 
Reaction mixtures were incubated at 95C for 10 min, followed by 40 cycles of 95C for 15 sec 
and 60C for 1 min. No template control sample was included, to enable detection of RNA 
and/or DNA contamination. Quantification of relative Rgs2 mRNA expression levels was carried 
out using the threshold-cycle difference method (ref. (31) and Applied Biosystems StepOne and 
StepOnePlus Real-Time PCR Systems Getting Started Guide for Relative Standard Curve and 
Comparative CT experiments), with β-actin as a normalization control. The Rgs2 and -actin 
gene primer pairs for RT-qPCR were OCH5082/OCH5083 and OCH5084/OCH5085, 
respectively (Table S3). 
 
In vivo ubiquitylation assay 
HeLa cells were transfected with pcDNA3.1 (control vector), or CH776 (a pcDNA3.1-
based plasmid expressing MQ-Rgs2ha), or pCH879 (expressing Teb43f) or pCH881 (expressing 
Teb4ଷ୤େଽ୅) (Table S2). After 24 hr, transfected cells were treated with 10 μM MG132 for 4 hr and 
thereafter lysed with RIPA buffer. Supernatants were immunoprecipitated with a monoclonal 
anti-ha antibody (Sigma), and were washed three times in RIPA buffer. Immunoprecipitates were 
fractionated by SDS-8% PAGE, followed by immunoblotting with anti-ubiquitin and/or rabbit 
polyclonal anti-ha antibodies. 
 
5 
 
RNAi-based Erk1/2 activation assay 
For RNAi (siRNA)-based Teb4 knockdown, HeLa cells (at ~70% confluence) in 6-well 
35-mm plates were transfected with 100 pmol of Teb4-specific siRNA using Lipofectamin 2000 
(Life technologies) for 24 hr. The cells were then co-transfected with 0.5 μg of M3 muscarinic 
acetylcholine receptor and 3 μg of either MQ-Rgs2ha or control (pcDNA3.1(+)) plasmids per 
well in the serum-free Opti-MEM  medium (Gibco). After 5 hr of transfection, the medium was 
replaced by DMEM containing 10% FBS. After incubation for 48 hr at 37C, HeLa cells were 
subject to serum starvation in DMEM with 25 mM HEPES (pH 7.2) for 24 hr, followed by 
addition of M3 agonist carbachol (Sigma-Aldrich) for 10 min at the final concentration of 
0.1 mM. Agonist-stimulated cells were washed twice in ice-cold phosphate-buffered saline (PBS) 
and thereafter lysed in RIPA buffer containing complete protease inhibitor cocktail (Roche) and 
phosphatase inhibitor mixture (Roche). Cells were then scraped into lysis buffer on ice and a 
lysate was clarified cell by centrifugation at 11,200g for 20 min at 4C. Equal amounts of total 
protein in 1x SDS-sample buffer were heated at 95C for 5 min, followed by SDS-10% 
Tris-glycine PAGE, and electrophoretic transfer onto PVDF membranes. The membranes were 
blocked for 1 hr at 4C in PBS buffer containing 0.1% Tween 20 and 3% bovine serum albumin 
(Sigma-Aldrich), followed by immunoblotting with anti-phospho Erk1/2 or anti-Erk1/2 
antibodies (Cell Signaling Technologies). 
 
Chemical crosslinking and coimmunoprecipitation analyses 
For crosslinking/coimmunoprecipitation assays, HeLa cell cultures (at ~75% confluence) 
in 10-cm dishes were co-transfected with 9 g of pCH879 (expressing Teb4f3) and 12 g of 
either pCH766, or pCH822, or pcDNA3.1 (see above). After incubation for 24 hr, cells were 
treated with MG132 at 10 M for 4 hr and thereafter with 1 mM Lomant’s reagent 
(dithiobis(succinimidylpropionate (DSP)), a cell-penetrating amino group-specific crosslinking 
reagent. The in vivo crosslinking reaction was carried out on ice for 2 hr and was stopped by the 
addition of 10 mM Tris-HCl (pH 7.5) for 15 min at 25C to quench unreacted DSP. Cells were 
gently scraped from plates, pelleted by low-speed centrifugation and lysed by resuspending them 
in 1 ml of buffer A (0.5% Triton X100, 0.15 M NaCl, 1 mM Na-EGTA, 0.1 mM MgCl2., 10 mM 
HEPES, pH 7.4), plus “complete protease inhibitor cocktail” (Roche)) and incubating on ice for 
20 min. The extracts were centrifuged at 11,200g for 20 min at 4°C and total protein 
concentrations in the supernatants were determined using Bradford assay (Bio-Rad). Samples 
containing 1 mg of total protein were incubated with anti-ha or anti-flag bound IgG Dynabeads 
(Life Technologies) at 4C for 16 hr and the magnetic beads were washed 3 times in buffer A. 
Captured proteins were eluted in 15 l of 0.1 M glycine-HCl (pH 2.8), followed by incubation in 
SDS-sample buffer containing 50 mM DTT for 30 min at 37C, SDS-10% PAGE and 
immunoblotting with anti-ha or anti-flag as described above. 
 
Purification of MQ-Rgs23-10-[GST] and GST-pulldown assays 
To produce and purify the conditionally Nα-terminally acetylated (Nt-acetylated) 
MQ-Rgs23-10-[GST] fusion, we employed an E.coli-based expression system. “Wild-type” 
E. coli very rarely Nt-acetylates heterologous eukaryotic proteins. In the resulting novel system, 
MQ-Rgs23-10-[GST] was expressed in E. coli either by itself or together with the cognate 
(Nt-acetylating the Met-Gln N-terminal sequence) NatB Nt-acetylase complex from the fission 
yeast Schizosaccharomyces pombe (32). The plasmid pCH3080, expressing MQ-Rgs23-10-[GST], 
was transformed into E. coli BL21(DE3) that carried either a vector plasmid (pACYCDuet 
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(pCH15)) or pCH3025 (32), which expressed the Naa20 and Naa25 subunits of the S. pombe 
NatB Nt-acetylase in E. coli. 
Overnight cultures (5 ml) of transformed E. coli were inoculated into LB medium 
(500 ml) containing chloramphenicol (34 g/ml) and kanamycin (50 g/ml), followed by growth 
at 37C to A600 of ~0.7. Expression of MQ-Rgs23-10-[GST] was then induced with 1 mM 
isopropyl -D-thiogalactoside (IPTG) at 30C for 4 hr. Cells were harvested by centrifugation 
and frozen at -80C. Cell pellets were thawed and resuspended in STE buffer (0.1 M NaCl, 
1 mM Na-EDTA, 10 mM Tris-HCl, pH 8.0) containing 1 mM DTT, 1mM phenylmethylsulfonyl 
fluoride (PMSF) and 1 mg/ml of chicken egg white lysozyme (Sigma). Cell suspensions were 
incubated on ice for 20 min and thereafter treated by sonication for 1 min 3 times, at 1-min 
intervals, followed by the addition of Triton X100 to the final concentration of 1%. After 
centrifugation at 11,200g for 20 min at 4C, the supernatants (~25 ml) were incubated with 1 ml 
of Glutathione Hicap agarose (50% slurry; Qiagen) at 4C for 2 hr. The beads were washed twice 
in 25 ml of the STE buffer. Carrier-bound GST or MQ-Rgs23-10-[GST] were eluted with 1 ml of 
STE buffer containing 10 mM glutathione (GSH), followed by overnight dialysis against storage 
buffer (10% glycerol, 0.15 M NaCl, 10 mM -mercaptoethanol, 50 mM HEPES, pH 7.5). The 
state of Nt-acetylation of the resulting MQ-Rgs23-10-[GST] fusion proteins was determined by 
MALD-TOF mass spectrometry. 
For GST-pulldown assays, 50 g of either GST, or MQ-Rgs23-10-[GST] (expressed in 
E. coli without S. pombe NatB), or (presumably) Nt-acetylated MQ-Rgs23-10-[GST] 
(coexpressed in E. coli with S. pombe NatB) were incubated with 50 l of the Glutathione Hicap 
agarose beads in GST-loading buffer (10% glycerol, 0.5 M NaCl, 1% NP40, 1 mM Na-EDTA, 
50 mM Tris-HCl, pH 8.0) at 4°C for 1 hr. The beads were washed once with 0.5 ml of the 
loading buffer and once with 0.5 ml GST-binding buffer (10% glycerol, 0.05% NP40, 50 mM 
NaCl, 50 mM Na-HEPES, pH 7.8). The beads in 0.2 ml-GST binding buffer were thereafter 
incubated at 4°C for 2 hr with 0.25 ml extracts from HeLa cell (2 mg of total protein) that 
expressed C-terminally triple flag-tagged (plus His6-tagged) Teb4. The beads were washed 3 
times in 0.5 ml of GST-binding buffer, followed by elution of bound proteins by the addition of 
15 l of 2xSDS-sample buffer and incubation for 30 min at 37C. The resulting samples were 
fractionated by SDS-8% PAGE and analyzed by immunoblotting with anti-flag antibody. The 
blotting membrane was also stained with Coomassie Brilliant Blue to verify the approximate 
equality of total protein loads vis-à-vis GST, MQ-Rgs23-10-[GST] and Ac-MQ-Rgs23-10-[GST]. 
 
Analysis of endogenous MQ-Rgs2 from human cells by mass spectrometry 
Purified human Rgs2 (~ 0.4 g; see the first section of Materials and Methods) was 
treated with 8 M Urea in 25 mM NH4HCO3 (pH 8.0) and thereafter reduced with 9.5 mM DTT in 
25 mM NH4HCO3 (pH 8.0) at 25C for 1 hr. Rgs2 was then alkylated with iodoacetamide (32 
mM) in NH4HCO3 (pH 8.0) at 25C for 1 hr in the dark, followed by quenching of excess 
unreacted iodoacetamide with DTT (40 mM) at 25C for 10 min. The sample was diluted 10-fold 
with 25 mM NH4HCO3 (pH 8.0), and 1 ml of the resulting sample was digested with of trypsin 
(1.2 g/ml) overnight at 37°C. Nt-acetylated peptides in the digested sample were analyzed by 
nanoflow liquid chromatography-tandem mass spectrometry (LC-MS/MS) using the LTQ 
Orbitrap Velos (Thermo Scientific) hybrid mass spectrometer. Nt-acetylation sites were assigned 
by manual inspection of MS/MS spectra and also using MaxQuant software (33). 
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Fig. S1. Conditional removal of N-terminal methionine from nascent proteins, their 
N-terminal acetylation, and the N-end rule pathway. 
(A) N-terminal processing of nascent proteins by Nα-terminal acetylases (Nt-acetylases) 
and Met-aminopeptidases (MetAPs). “Ac” denotes the Nα-terminal acetyl moiety. M, methionine 
(Met) residue. X and Z, single-letter abbreviations for any amino acid residue. Yellow ovals 
denote the rest of a protein molecule. MetAPs cotranslationally remove N-terminal Met from a 
nascent protein unless the side chain of a residue at position 2 is bulkier than Val, in which case 
Met is retained (12, 34). 
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(B) Functional complementarity between the Arg/N-end rule pathway and the Ac/N-end 
rule pathway for proteins bearing the N-terminal MФ motif, i.e., unacetylated N-terminal Met 
followed by a bulky hydrophobic (Ф) residue. This motif is targeted by the Arg/N-end rule 
pathway (16). Because the Met-Ф motif is also a substrate of the NatC Nt-acetylase (Fig. S2), 
Met-Ф proteins are usually Nt-acetylated at least in part, thereby acquiring the previously 
characterized Ac/N-degrons (13, 16). Thus, both Nt-acetylated and unacetylated versions of the 
same Met-Ф protein can be destroyed, either by the Ac/N-end rule pathway or by the 
“complementary” Arg/N-end rule pathway (16). 
(C, D) The mammalian N-end rule pathway. The main determinant of an N-degron is a 
destabilizing N-terminal residue of a protein. Recognition components of the N-end rule 
pathway, called N-recognins, are E3 ubiquitin ligases that can recognize N-degrons. 
Regulated degradation of proteins or their fragments by the N-end rule pathway mediates 
a strikingly broad range of functions, including the sensing of heme, nitric oxide, oxygen, and 
short peptides; control of protein quality and subunit stoichiometries, including the elimination 
of misfolded proteins; regulation of signaling by G proteins; repression of neurodegeneration; 
regulation of apoptosis, chromosome cohesion/segregation, transcription, and DNA repair; 
control of peptide import; regulation of meiosis, autophagy, immunity, fat metabolism, cell 
migration, actin filaments, cardiovascular development, spermatogenesis, and neurogenesis; the 
functioning of adult organs, including the brain, muscle and pancreas; and the regulation of many 
processes in plants (references (12-14, 16, 18, 20, 35-88) and references therein). In eukaryotes, 
the N-end rule pathway consists of two branches, the Ac/N-end rule pathway and the Arg/N-end 
rule pathway. 
(C) The Ac/N-end rule pathway. This diagram illustrates the mammalian Ac/N-end rule 
pathway through extrapolation from its S. cerevisiae version. As described in the main text, the 
Ac/N-end rule pathway has been identified only in S. cerevisiae (13, 15, 16), i.e., the presence of 
this pathway in mammals and other multicellular eukaryotes was conjectural, until the present 
work. Red arrow on the left indicates the removal of N-terminal Met by Met-aminopeptidases 
(MetAPs). N-terminal Met is retained if a residue at position 2 is nonpermissive (too large) for 
MetAPs. If the retained N-terminal Met or N-terminal Ala, Ser, Thr are followed by 
acetylation-permissive residues, the above N-terminal residues are Nα-terminally acetylated 
(Nt-acetylated) by ribosome-associated Nt-acetylases (21, 89, 90). Nt-terminal Val and Cys are 
Nt-acetylated relatively rarely, while N-terminal Pro and Gly are almost never Nt-acetylated. 
(N-terminal Gly is often N-myristoylated.) N-degrons and N-recognins of the Ac/N-end rule 
pathway are called Ac/N-degrons and Ac/N-recognins, respectively (12). The term “secondary” 
refers to Nt-acetylation of a destabilizing N-terminal residue before a protein can be recognized 
by a cognate Ac/N-recognin. As described in the main text, the human Teb4 E3 ubiquitin ligase 
was identified, in the present study, as an Ac/N-recognin of the mammalian Ac/N-end rule 
pathway. Natural Ac/N-degrons are regulated at least in part by their reversible steric shielding 
in protein complexes (15, 16). 
(D) The Arg/N-end rule pathway. The prefix “Arg” in the pathway’s name refers to 
N-terminal arginylation (Nt-arginylation) of N-end rule substrates by the Ate1 arginyltransferase 
(R-transferase), a significant feature of this proteolytic system. The Arg/N-end rule pathway 
targets specific unacetylated N-terminal residues. In the yeast S. cerevisiae, the Arg/N-end rule 
pathway is mediated by the Ubr1 N-recognin, a 225 kDa RING-type E3 ubiquitin ligase and a 
part of the targeting apparatus comprising a complex of the Ubr1-Rad6 and Ufd4-Ubc4/5 
holoenzymes (12, 14, 18). In multicellular eukaryotes several functionally overlapping E3 
ubiquitin ligases (Ubr1, Ubr2, Ubr4, Ubr5) function as N-recognins of this pathway. An 
N-recognin binds to the “primary” destabilizing N-terminal residues Arg, Lys, His, Leu, Phe, 
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Tyr, Trp and Ile. In contrast, the N-terminal Asn, Gln, Asp, and Glu residues (as well as Cys, 
under some metabolic conditions) are destabilizing owing to their preliminary enzymatic 
modifications. These modifications include the Nt-deamidation of N-terminal Asn and Gln by 
the Ntan1 and Ntaq1 Nt-amidases, respectively, and the Nt-arginylation of N-terminal Asp and 
Glu by the Ate1 R-transferase, which can also Nt-arginylate oxidized Cys, either Cys-sulfinate or 
Cys-sulfonate. They can form in animal and plant cells through oxidation of Cys by nitric oxide 
(NO) and oxygen, and also by N-terminal Cys-oxidases (19, 44, 52, 59, 61, 91-93). In addition to 
its type-1 and type-2 binding sites that recognize, respectively, the basic and bulky hydrophobic 
unacetylated N-terminal residues, an N-recognin such as Ubr1 contains other substrate-binding 
sites as well. These sites recognize substrates that are targeted through their internal 
(non-N-terminal) degrons, as indicated on the diagram (12). Hemin (Fe3+-heme) binds to the 
Ate1 R-transferase, inhibits its Nt-arginylation activity and accelerates its in vivo degradation. 
Hemin also binds to Ubr1 (and apparently to other N-recognins as well) and alters its functional 
properties, in ways that remain to be understood (43). As shown in the diagram, the unacetylated 
Met of the N-terminal MФ motif is recognized by both yeast and mammalian Ubr1; this 
capability greatly expands the substrate range of the Arg/N-end rule pathway (16).  
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Fig. S2. Specificities and subunit compositions of Nα-terminal acetylases 
(Nt-acetylases). 
(A) Substrate specificities of S. cerevisiae Nt-acetylases. “Ac” denotes the Nα-terminal 
acetyl moiety. The bulk of Nt-acetylases are associated with ribosomes (94, 95). The specificities 
of mammalian Nt-acetylases are similar to those of their yeast counterparts, but an individual 
mammalian genome encodes more than ten Nt-acetylases, in contrast to four in S. cerevisiae. 
Some mammalian Nt-acetylases, such as NatF (its catalytic subunit is called Naa60 (see 
fig. S4H, I)) (22), can Nt-acetylate N-terminal motifs that include Met-Lys or Met-Arg, which 
are rarely if ever Nt-acetylated in S. cerevisiae. This compilation of Nt-acetylases and their 
specificities is derived from data in the literature ((21, 89, 90, 96-108) and references therein). 
(B) Subunits of S. cerevisiae Nt-acetylases. This paper employs the revised nomenclature 
for subunits of Nt-acetylases (109) and cites older names of these subunits in parentheses. 
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Fig. S3. The targeting of MX-Rgs2 proteins by the yeast and human Ac/N-end rule 
and Arg/N-end rule pathways. 
(A) CHX chases with the hypertension-associated mutant human ML-Rgs2ha in 
wild-type, naa30Δ, ubr1Δ, and naa30Δ ubr1Δ S. cerevisiae.  
(B) As in A but in human HeLa cells with wild-type human MQ-Rgs2ha and 
hypertension-associated mutants MR-Rgs2ha and ML-Rgs2ha. 
(C) HeLa cells expressing MQ-Rgs2ha or PQ-Rgs2ha together with Teb43f were treated 
with a cell-penetrating crosslinker, followed by immunoprecipitations with anti-flag, reversal of 
crosslinks, SDS-PAGE, and immunoblotting with anti-ha and anti-flag (see also Fig. 2H and 
Materials and Methods). Note the coimmunoprecipitation of MQ-Rgs2ha with Teb43f, and the 
absence of coimmunoprecipitation of PQ-Rgs2ha. 
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(D) Quantification of data in A. 100% corresponded to the zero-time level of ML-Rgs2ha 
in naa30Δ ubr1Δ S. cerevisiae. 
(E) Quantification of data in B. 100% corresponded to the zero time level of PQ-Rgs2ha 
in HeLa cells.  
In every set of degradation curves shown in this figure and in the main Figs. 1 and 3, 
100% at zero time was chosen to correspond to the relative initial level of the most slowly 
degraded test protein in a given set. Panel A (quantified in D) and panel B (quantified in E) show 
the results of CHX-chases that were independently carried out counterparts of CHX-chases that 
are shown in the main Fig. 1B (quantified in D) and 1F (quantified in E), respectively. These 
comparisons illustrate qualitative reproducibility of independently generated data (particularly 
the robustly reproduced order of metabolic stabilities of specific test proteins in specific genetic 
backgrounds), which differed in relatively minor aspects of corresponding degradation curves. In 
our extensive experience with repeated CHX-chases and 35S-pulse-chases in either S. cerevisiae 
or HeLa cells, a strictly quantitative reproducibility of independently produced and measured 
chase-degradation patterns remains the aim to be reached. 
(F) Extracts from HeLa cells expressing MQ-Rgs2ha in the presence or absence of 
coexpressed Teb43f or Teb4ଷ୤େଽ୅ and in the presence of the MG132 proteasome inhibitor, as 
indicated. MQ-Rgs2ha was immunoprecipitated from extracts using anti-ha antibody, followed 
by SDS-PAGE and immunoblotting with anti-ubiquitin antibody to detect polyubiquitin chains 
linked to MQ-Rgs2, and with anti-flag, anti-ha and anti-tubulin antibodies as well, as shown. 
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Fig. S4. Degradation assays with MX-Rgs2 proteins in HeLa cells subjected to 
RNAi of specific Nt-acetylases and Teb4. 
(A) CHX-chases with endogenous (not overexpressed) MQ-Rgs2 in HeLa cells subjected 
to RNAi-mediated knockdowns of endogenous Teb4 or Naa20 (NatB). 
(B) Same as in A but CHX-chases with transiently expressed (exogenous) MQ-Rgs2ha. 
(C) Relative steady-state levels of exogenous wild-type MQ-Rgs2ha and its MR-Rgs2ha 
and ML-Rgs2ha mutants in HeLa cells transfected with equal amounts of MX-Rgs2ha plasmids. 
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(D) ML-Rgs2ha expressed in HeLa cells in the presence of the coexpressed wild-type 
Teb43f or Teb4ଷ୤େଽ୅. Note a strong decrease of ML-Rgs2ha in the presence of wild-type Teb43f but 
not in the presence of its inactive missense mutant Teb4ଷ୤େଽ୅. Note also a much lower steady-state 
level of active Teb43f (in comparison to the inactive Teb4ଷ୤େଽ୅), owing to the previously described 
self-targeting of active Teb4 for degradation (24). 
(E) Same as in D but with MR-Rgs2ha. 
(F) Quantification of data in C (relative levels of the three MX-Rgs2ha proteins). 
(G) Same as in F but quantification, using qRT-PCR, of the relative levels of mRNAs 
encoding the three MX-Rgs2ha proteins. Standard errors of means (SEMs), with qRT-PCR 
assays in triplicate for each sample, are indicated as well. 
(H) Steady-state levels of transiently expressed (exogenous) MR-Rgs2ha in HeLa cells 
subjected to RNAi-mediated knockdowns of either endogenous Naa60, the cognate (for 
MR-Rgs2ha) NatF Nt-acetylase, or endogenous Naa20, the non-cognate (for MR-Rgs2ha) NatB 
Nt-acetylase. Note the increase in MR-Rgs2ha in response to RNAi of Naa60 but not of Naa20. 
(I) Same as in H but with MK-Rgs2ha, a derivative of wild-type MQ-Rgs2ha not 
encountered, thus far, among human patients, that contained another basic residue at position 2.  
(J) 35S-pulse-chases with MX-Rgs2ha (X=R, Q, L) in HeLa cells.  
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Fig. S5. Mass spectrometric analyses of Nt-acetylation of MQ-Rgs2 and 
MQ-Rgs21-10-[GST]. (A) Wild-type MQ-Rgs2ha purified from human HEK293 cells is Nt-
acetylated. (B) Non-Nt-acetylated (upper panel) and Nt-acetylated MQ-Rgs21-10-[GST] fusion 
(lower panel) purified from E. coli that either lacked or expressed, respectively, the 
Schizosaccharomyces pombe NatB Nt-acetylase (see Materials and Methods). 
  
16 
 
 
 
 
Fig. S6. Rgs2, Teb4, N-terminal acetylation, and the N-end rule pathway. Rgs2 and 
Teb4 are, respectively, a substrate and Ac/N-recognin of the mammalian Ac/N-end pathway. 
Only some Rgs2-regulated processes (including the Gαq-mediated activation of Erk1/2 kinase) 
are shown. Both wild-type MQ-Rgs2 and its hypertension-associated mutant MR-Rgs2 (the 
latter is not shown) are Nt-acetylated and conditionally destroyed by the Teb4-mediated 
Ac/N-end rule pathway. In contrast, another hypertension-associated mutant, ML-Rgs2, is 
targeted by both the Ac/N-end rule pathway and the Arg/N-end rule pathway (see the main text) 
(fig. S1C, D). Some abbreviations: IP3, inositol trisphosphate. DAG, diacyglycerol. 
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Fig. S7. Mammalian RGS proteins as identified or predicted N-end rule substrates. 
Human RGS proteins as identified or possible (predicted) substrates of either the 
Ac/N-end rule pathway, or the Arg/N-end rule pathway, or both pathways at the same time, 
depending on the Nt-acetylation status of a specific RGS protein. See also the main text. 
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Table S1.  S. cerevisiae strains used in this study. 
Strains Relevant genotypes Sources 
JD53 MAT trp1- 63 ura3-52 his3- 200 leu2-3112. lys2-801 (110) 
BY4742 MAT his3-1 leu2-0 lys2-0 ura3-0 can1-100 Open Biosystems, Inc. 
CHY223 doa10::kanMX6 in JD53 (13) 
CHY272 naa30::kanMX4 in BY4742 Open Biosystems, Inc. 
CHY345 ubr1::LEU2 in BY4742 (16) 
CHY349 naa30::kanMX4 ubr1::LEU2 in BY4742 (16) 
CHY367 naa20::natNT2 in JD53 This study 
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Table S2. Plasmids used in this study. 
Plasmids Descriptions Sources 
pCH12 pET30a Novagen, Inc. 
pCH15 pACYCDuet Novagen, Inc. 
pCH61 pcDNA3.1(+) with ha2 Hwang’s lab collection 
pCH692 p316CUP1 Hwang’s lab collection 
pCH759 Teb4 in pcDNA3.1 myc/His (-) (24) 
pCH760 Teb4C9A in pcDNA3.1 myc/His(-) (24) 
pCH766 MQ-Rgs2ha in pcDNA3(+) (11) 
pCH767 ML-Rgs2ha in pcDNA3(+) (11) 
pCH768 MR-Rgs2ha in pcDNA3(+) (11) 
pCH821 MPQ-Rgs2ha in pcDNA3(+) This study 
pCH879 Teb4f3h in pcDNA3.1 This study 
pCH881 Teb4C9Af3h in pcDNA3.1 This study 
pCH3002 MQ-Rgs2-GST in pACYCDuet This study 
pCH3015 pET30a Qiagen, Inc. 
pCH3025 S. pombe Naa20+-NAA25+ in 
pACYCDuet 
(32) 
pCH3056 MQ-Rgs2-GST in pET30a This study 
pCH3080 MQ-Rgs21-10-GST in pET30a This study 
pCH3132 M3ha2 in pcDNA3.1(+) This study 
pCH5050 MQ-Rgs2ha in pRS316, with PCUP1 This study 
pCH5051 ML-Rgs2ha in pRS316, with PCUP1 This study 
pCH5064 Gαqha2 in pcDNA3.1(+) This study 
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Table S3. Some PCR primers used in this study. 
Name Primer sequences 
OCH1091 5’-CTTGGTACCATG CCA CAAAGTGCTATGTTCTTGGCTGTT-3’ 
OCH1100 
5’-
AACCTCGAGCTAAGCGTAATCTGGAACATCGTATGGGTAAGAACC
TGTAGCATGAGGCTCTGTGGTGAT-3’ 
OCH1265 
5’-
GGTAAGCTTGACTATAAAGACCATGACGGTGATTATAAAGATCAT
GATATCGATTACAAG-3’ 
OCH1266 
5’-
AATCTTAAGTTAATGATGGTGATGGTGATGAGAACCCTTGTCATC
GTCATCCTTGTAATC-3’ 
OCH1514 5'-TATCTCGAGTCATTTTGGAGGATGGTCGCCACCACC -3' 
OCH3006 5’-TCCCATATGCAAAGTGCTATGTTCTTGGCTGTT-3’ 
OCH3013 5’-CGCGGATCCTGTAGCATGAGGCTCTGTGGTGAT-3’ 
OCH3015 5’-CGCGGATCCATGTCCCCTATACTAGGTTATTGG-3’ 
OCH3095 
5'-
TCCCATATGCAAAGTGCTATGTTCTTGGCTGTTCAATCCCCTATAC
TAGGTTATTGG-3' 
OCH3178 5’-ACAGGATCCATGACCTTGCACAATAACAGTAC-3’ 
OCH3179 5’-ACATCTAGACAAGGCCTGCTCGGGTGCGCGCTTG-3’ 
OCH5070 5’-CCCGGATCCATGCAAAGTGCTATGTTCTTGGCT-3’ 
OCH5071 5’-CCCGGATCCATGTTAAGTGCTATGTTCTTGGCTGTTCAA-3’ 
OCH5073 
5’-
CCCGAGCTCCTAAGCGTAATCTGGAACATCGTATGGGTAGCTAGC
TGTAGCATGAGG CTCTGTGGTGAT-3’ 
OCH5090 5’-GTCGGTACCATGACTCTGGAGTCCATCATGGCG-3’ 
OCH5091 5’-GCTCTCGAGGACCAGATTGTACTCCTTCAGGTT-3’ 
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